结论 RIP1-RIP3-MLKL信号通路在HF患者中表达明显增加,与HF严重程度呈正相关;慢性HF的发生、发展及预后可能与RIP1/RIP3-MLKL信号通路的激活与表达有关。 关键词: 慢性心力衰竭;RIP1;RIP3;MLKL;程序性坏死 Abstract: Objective To detect plasma levels of receptor-interacting protein kinase 1 (RIP1), RIP3...
Overexpression of RIP1 weakened the effect of picroside II on DEX induced hFOB 1.19 cells. Conclusion Picroside II reduces inflammation by down-regulating RIP1/RIP3/MLKL pathway, thus inhibiting the apoptosis of osteoblasts induced by DEX.陈鹏...
Necrosulfonamide 阻止 MLKL-RIP1-RIP3 坏死小体复合体与其下游效应子相互作用。MLKL 是诱导坏死过程中 RIP3 的重要底物。 生物活性:Necrosulfonamide 是一种坏死性凋亡抑制剂,通过选择性靶向混合谱系激酶结构域样蛋白(MLKL)发挥作用。 Necrosulfonamide 可防止 MLKL-RIP1-RIP3 necrosome 复合物与其下游效应子相互作用。
RIP1,RIP3,MLKL,P-MLKL mRNA 和蛋白表达情况,明确 Rg1 对CFs程序性坏死中RIP1和RIP3的调控作用.结果:1.房颤患者心肌组织中纤维化和程序性坏死检测:与SR组相比,AF组中HE,Masson和Sirius red染色的病理指标均明显升高(P<0.05);COL1,α-SMA,RIP1,RIP3,MLKL,P-MLKL 的 mRNA 明显升高(P<0.05),COL1,α-...
结果RIP1特异性抑制剂Nec-1和柚皮素可阻断RIP1磷酸化活化,抑制RIP1-RIP3-MLKL信号通路,并降低PCOS大鼠炎症水平,缓解卵巢颗粒细胞坏死及凋亡(P<0.05)。Z-VAD-fmk可促进RIP1-RIP3-MLKL途径活化,加重卵巢颗粒细胞凋亡,并部分减弱柚皮素的抗卵巢颗粒细胞凋亡作用(P<0.05)。结论柚皮素可能通过阻断RIP1-RIP3-MLKL...
达格列净(Dapagliflozin)通过抑制RIP1--RIP3--MLKL信号轴减轻单侧输尿管梗阻坏死炎症和肾纤维化 来自 万方 喜欢 0 阅读量: 4 作者: 内科学 摘要: 目的:达格列净(Dapagliflozin)是一种钠-葡萄糖协同转运2(sodium-glucose cotrans porter 2,SGLT2)抑制剂,已被证明在糖尿病肾病中起到保护作用.然而,在非糖尿病...
MLKLVinblastine (VBL) has been considered as a first-line anti-tumor drug for many years. However, vinblastine-caused myocardial damage has been continually reported. The underlying molecular mechanism of the myocardial damage remains unknown. Here, we show that vinblastine induces myocardial damage ...
Ultimately, the phosphorylated MLKL forms an oligomer, which causes cellular membrane leakage and cell death[10-13]. Thus, necrosome formation is a key step leading to necropto- sis, but the factors affecting the interaction between RIP1 and RIP3 are still unclear. Shikonin, a naphthoquinone ...
Finally, supplementation with the mitochondrial metabolite α-ketoglutarate, whose synthesis is regulated by RIP1/RIP3/MLKL, rescues cells from the sensitizing effect of Nec-1 and NSA. Together, this study identifies a previously unrecognized novel regulated necrotic death pathway that involves ...
Tissue plasminogen activator (tPA), a thrombolytic drug that breaks down the clot, is the only drug approved by the FDA for the treatment of ischemic stroke [2]. However, the therapeutic window of tPA lies within 4.5 h of the onset of stroke symptoms [3]. The administration of the drug...